Re-Thinking the Pipeline: Development in the Age of AI
In this article, AustinPx’s CEO, Elizabeth Hickman, examines how artificial intelligence is reshaping the front end of drug discovery and what that shift means for development. AI-driven tools are enabling researchers to design and evaluate increasingly complex molecules at unprecedented speed, expanding access to targets that were once considered undruggable. However, many of these AI-designed…
Read MoreFrom In Silico to In Vivo: Why Development Strategy Now Determines AI-Era Success
In this article, AustinPx CSO Dave Miller examines how artificial intelligence (AI) is reshaping the front end of drug discovery while exposing a growing gap between faster candidate generation and real-world developability. As AI helps researchers design increasingly complex molecules, formulation, stability, manufacturability, and scale-up challenges still determine whether those candidates can become viable medicines.…
Read MoreHow CDMOs Turn “Undruggable” Into “Developable”
AustinPx CEO Elizabeth Hickman and CSO Dave Miller examine how precision medicine, AI, and advanced discovery tools are expanding what is possible in drug development while creating new formulation and manufacturing challenges. As researchers pursue more targeted molecules, many candidates come with difficult chemistry, including poor solubility, low permeability, stability concerns, and scale-up risk. The…
Read More